Bimatoprost Ophthalmic Solution (BOS) 0.3 mg w/v for 1 Open Trial of Long-term Preventive Therapy of Migraine in 3 patients with Pathophysiologic Shift from Brain to Eye
Crossref DOI link: https://doi.org/10.29328/journal.jnnd.1001087
Published Online: 2023-11-09
Published Print: 2023-11-09
Update policy: https://doi.org/10.29328/crossmark-policy
Vinod Kumar, Gupta https://orcid.org/0000-0002-6770-5916
